Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00074191 · ClinicalTrials.gov registry record · Phase 2

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

A Phase 2 study of Lymphoma, sponsored by OHSU Knight Cancer Institute.

Completed
Registry status
Phase 2
Development phase
1
Enrollment target
1
Study location

NCT00074191 is a Phase 2 study of Lymphoma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 1 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00074191, a Phase 2 study of Lymphoma, has completed, sponsored by OHSU Knight Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
1 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have primary CNS lymphoma.

Conditions Studied

Interventions

  • DRUG dexamethasone
  • DRUG methotrexate
  • DRUG cytarabine
  • DRUG lomustine
  • DRUG procarbazine hydrochloride

Study Locations (1)

Oregon

  • Oregon Health & Science University Cancer Institute - Portland

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2000-01
Est. Completion 2000-10
Phase Phase 2

Sponsor

OHSU Knight Cancer Institute

211 total trials

What the Registry Record Tells You About NCT00074191

The ClinicalTrials.gov registry entry for NCT00074191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which dexamethasone is the first listed.

NCT00074191 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT00074191 about?

NCT00074191 is a clinical study titled "Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy, such as methotrexate, procarbazine, lomustine, dexamethasone, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effec...

What is the current status of trial NCT00074191?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2000-01. Estimated completion is 2000-10.

What conditions does trial NCT00074191 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT00074191?

The interventions under investigation include: dexamethasone (DRUG), methotrexate (DRUG), cytarabine (DRUG), lomustine (DRUG), procarbazine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00074191?

This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00074191 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.